Oral curcumin did not prevent radiation dermatitis in a large trial

The study and its comparison

A randomized trial included 686 participants. The study population was breast cancer patients receiving radiation therapy. Researchers compared oral curcumin 6 g daily versus placebo, with follow-up over radiotherapy through one week afterward. [1]

Dermatitis severity at the end of radiation did not differ significantly. Pain, symptom and quality-of-life comparisons were also negative. Fewer severe reactions with curcumin represented a nonsignificant trend, not a confirmed benefit. [1]

What the finding establishes

The trial tested oral capsules rather than topical turmeric oil or cosmetic skincare. Its negative primary result should lead the interpretation even when a selected severity subgroup appears favorable. The authors declared no conflicts; full funding was not independently established from the retrieved record. [1]

A hypothetical distinction

Imagine a subgroup has fewer severe events but its comparison is not significant. It cannot reverse the conclusion from the prespecified primary endpoint.

Interpretation checklist — Oral curcumin did not prevent radiation dermatitis in a large trial
Detail	Interpretation
Measured outcome	Keep the endpoint specific
Study preparation	Not every retail product
Remaining uncertainty	Not resolved by a mechanism

Oral curcumin did not prevent radiation dermatitis in a large trial — original article outline diagram — Original editorial diagram of this article’s sections; no product photograph or clinical finding is depicted.

Sources for this article

Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.